Freedom from Cancer Startup Challenge
  • Home
  • Winners
  • Overview
    • Key Dates
    • Phase 0 - Enter Challenge
    • Phase 1 - Elevator Speech
    • Phase 2 - Business Plan
    • Phase 3 - Start-up
  • Mavens
    • Ambassadors
    • Apply as Maven
  • About Us
    • Contact Us
    • Testimonials
    • News
    • Blog
  • Home
  • Winners
  • Overview
    • Key Dates
    • Phase 0 - Enter Challenge
    • Phase 1 - Elevator Speech
    • Phase 2 - Business Plan
    • Phase 3 - Start-up
  • Mavens
    • Ambassadors
    • Apply as Maven
  • About Us
    • Contact Us
    • Testimonials
    • News
    • Blog
Search by typing & pressing enter

YOUR CART

RETURN TO ALL INVENTIONS LIST
RETURN TO THERAPEUTICS ​LIST
Methods and compositions for the treatment of glutamine-addicted cancers
Patent Number: US20160022708

Executive Summary:
  • Invention Type: Therapeutic
  • Patent Status: US Grant
  • Patent Link: https://patents.google.com/patent/US20160022708/
  • Research Institute: St. Jude Children’s Research Hospital
  • Disease Focus: Glutamine-addicted cancers, including neuroblastoma or Ewing’s sarcoma
  • Basis of Invention: Combining a glutaminase antagonist and a pro-apoptotic compound causes synergistic cytotoxicity
  • How it works: The glutaminase antagonist is 6-diazo-5-oxo-1-norleucine (DON) and the pro-apoptotic compound is a Bcl-2 family member antagonist (obatoclax mesylate, navitoclax, or fenretinide)
  • Lead Challenge Inventor: Kevin Freeman
  • Development Stage: Preclinical (mouse xenograft models)
  • Novelty: Novel combination therapy
  • Clinical Applications: Treatment of neuroblastoma or Ewing’s sarcoma

General Description:

Neuroblastoma and Ewing’s sarcoma, together cause 18% of all pediatric cancer death. This novel combination therapy exploits glutamine addiction – particularly associated with Myc deregulation – to specifically kill tumor cells.

Scientific Progress:
In vitro and in mouse xenograft models, high-Myc expressing tumors are susceptible to DON-induced apoptosis. Antagonists to Bcl-2 family members synergize the cytotoxic effect of DON.

Future Directions:
  • Clinical trial

Strengths:
  • Those drugs are FDA-approved or in clinical trials, therefore the PK/PD and the side effects are known in human
  • New clinical indications

Weaknesses:
  • Combination therapy of commercially available drugs
 
Patent Status:
Legal Status: Pending
  • Priority date: 2013.03.14
  • Filing date: 2014.03.13
  • Publication date: 2016.01.28

Publication PMID:
25615615

Publications:

Olsen RR, Mary-Sinclair MN, Yin Z, Freeman KW. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism. PLoS One. 2015 Jan 23;10(1):e0116998. doi: 10.1371/journal.pone.0116998. eCollection 2015.

Inventor Bio: Kevin Freeman
https://www.stjude.org/directory/f/kevin-freeman.html
Powered by Create your own unique website with customizable templates.